Viewing data from:

VPRIV

BLA

VELAGLUCERASE ALFA | B022575 | SHIRE HUMAN GENETIC

2 products0 Purple Book patents

Biologic LOENo LOE data

No exclusivity dates or listed patents found in Purple Book

Purple Book Patents

No listed patents in Purple Book.

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Purple Book (Biologics)

BLA 22575 | 2 presentations

351(a) ReferenceLicensedCDERFor Injection

Proper Name

velaglucerase alfa

Applicant

Takeda Pharmaceuticals U.S.A., Inc.

Approval Date

26-Feb-10

400UNITS — Single-Dose Vial (Intravenous)

200UNITS — Single-Dose Vial (Intravenous)

Source: FDA Purple Book (purplebooksearch.fda.gov).

Approval Letters

10 letters from Drugs@FDA

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — 400 UNITS/VIAL

▴

INJECTABLE;INTRAVENOUS | Approved: 2010-02-26 00:00:00

No patent or exclusivity listings for this strength.

#002 — 200 UNITS/VIAL

▾

POWDER;INTRAVENOUS | Approved: 2010-02-26 00:00:00